A meta-analysis reveals the protein profile associated with malignant transformation of oral leukoplakia.
malignant transformation
meta-analysis
oral cancer
oral leukoplakia
proteins
systematic review
Journal
Frontiers in oral health
ISSN: 2673-4842
Titre abrégé: Front Oral Health
Pays: Switzerland
ID NLM: 9918227262706676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
02
11
2022
accepted:
16
01
2023
entrez:
16
3
2023
pubmed:
17
3
2023
medline:
17
3
2023
Statut:
epublish
Résumé
The search for biomarkers associated with oral leukoplakia malignant transformation is critical for early diagnosis and improved prognosis of oral cancer patients. This systematic review and meta-analysis aimed to assess protein-based markers potentially associated with malignant transformation of oral leukoplakia. Five database and the grey literature were searched. In total, 142 studies were included for qualitative synthesis, where 173 proteins were investigated due to their potential role in malignant progression from oral leukoplakia (OL) to oral squamous cell carcinoma (OSCC). The abundance of these proteins was analyzed in fixed tissues and/or biofluid samples, mainly by immunohistochemistry and ELISA, and 12 were shared by both samples. Enrichment analysis revealed that the differential abundant proteins are mostly involved with regulation of cell death, regulation of cell proliferation, and regulation of apoptotic process. Also, these proteins are mainly expressed in the extracellular region (55.5%), cell surface (24.8%), and vesicles (49.1%). The meta-analysis revealed that the proteins related to tumor progression, PD-L1, Mdm2, and Mucin-4 were significantly associated with greater abundance in OSCC patients, with an Odds Ratio (OR) of 0.12 (95% CI: 0.04-0.40), 0.44 (95% CI: 0.24-0.81), and 0.18 (95% CI: 0.04-0.86), respectively, with a moderate certainty of evidence. The results indicate a set of proteins that have been investigated across OSCC initiation and progression, and whose transcriptional expression is associated with clinical characteristics relevant to the prognosis and aggressiveness. Further verification and validation of this biomarkers set are strongly recommended for future clinical application.
Identifiants
pubmed: 36923449
doi: 10.3389/froh.2023.1088022
pmc: PMC10008949
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1088022Informations de copyright
© 2023 Normando, dos Santos, Sá, Busso-Lopes, De Rossi, Patroni, Granato, Guerra, Santos-Silva, Lopes and Paes Leme.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Commun. 2018 Sep 5;9(1):3598
pubmed: 30185791
Exp Mol Pathol. 2006 Oct;81(2):123-30
pubmed: 16822500
J Oral Pathol Med. 2014 Jul;43(6):427-34
pubmed: 24456424
Am J Pathol. 2005 Mar;166(3):913-21
pubmed: 15743802
J Clin Med. 2020 Mar 21;9(3):
pubmed: 32245251
J Cancer Res Ther. 2012 Jan;8 Suppl 1:S123-5
pubmed: 22322730
J Oral Pathol Med. 2011 Sep;40(8):629-35
pubmed: 21435003
Head Neck. 2020 Mar;42(3):539-555
pubmed: 31803979
Cancer Biother Radiopharm. 2019 Sep;34(7):444-450
pubmed: 31170012
Ann Diagn Pathol. 2013 Feb;17(1):45-50
pubmed: 22818026
Pathol Res Pract. 2019 Jun;215(6):152418
pubmed: 31027907
Mol Cell Proteomics. 2021;20:100004
pubmed: 33578082
Appl Immunohistochem Mol Morphol. 2021 Oct 1;29(9):706-712
pubmed: 34008487
Surg Oncol. 2020 Mar;32:99-107
pubmed: 31983439
Int J Oncol. 2011 Dec;39(6):1391-9
pubmed: 21833468
Histol Histopathol. 2006 Jul;21(7):721-8
pubmed: 16598671
Proteomics. 2016 Jan;16(1):159-73
pubmed: 26552850
Asian Pac J Cancer Prev. 2019 Jul 01;20(7):2087-2093
pubmed: 31350970
Mod Pathol. 2017 Dec;30(12):1646-1654
pubmed: 28799537
Clin Proteomics. 2020 May 24;17:17
pubmed: 32489335
Int J Oral Maxillofac Surg. 2020 Dec;49(12):1525-1534
pubmed: 32360101
Head Neck. 2009 Aug;31(8):1039-48
pubmed: 19340865
Sci Rep. 2016 May 26;6:26757
pubmed: 27225603
Indian J Dent Res. 2014 May-Jun;25(3):305-10
pubmed: 25098985
J Oral Pathol Med. 2007 Nov;36(10):575-80
pubmed: 17944749
J Clin Med. 2021 Apr 13;10(8):
pubmed: 33924500
J Proteomics. 2020 Feb 10;212:103574
pubmed: 31706945
Scientifica (Cairo). 2015;2015:135298
pubmed: 26558136
J Cancer Res Ther. 2018 Jan-Mar;14(2):388-393
pubmed: 29516925
J Oral Sci. 2005 Jun;47(2):71-6
pubmed: 16050486
Oral Dis. 2021 Nov;27(8):1862-1880
pubmed: 33128420
J Cancer Res Ther. 2020 Apr-Jun;16(3):569-574
pubmed: 32719269
J Oral Pathol Med. 2018 Aug;47(7):633-640
pubmed: 29738071
Oral Oncol. 2006 Feb;42(2):147-53
pubmed: 16246616
Biomedicines. 2021 Feb 16;9(2):
pubmed: 33669300
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
J Clin Med. 2019 Oct 21;8(10):
pubmed: 31640140
J Oral Maxillofac Pathol. 2016 Jan-Apr;20(1):71-7
pubmed: 27194865
J Investig Clin Dent. 2014 Aug;5(3):214-9
pubmed: 23776093
J Oral Maxillofac Pathol. 2019 Jan-Apr;23(1):159
pubmed: 31110440
Hum Immunol. 2017 Nov;78(11-12):752-757
pubmed: 28941745
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Crit Rev Oncol Hematol. 2020 Sep;153:102986
pubmed: 32682268
J Oral Pathol Med. 2016 Mar;45(3):155-66
pubmed: 26189354
J Clin Oncol. 2008 Jan 20;26(3):354-60
pubmed: 18202409
Mol Clin Oncol. 2020 Nov;13(5):42
pubmed: 32874572
Cureus. 2020 Apr 5;12(4):e7551
pubmed: 32382455
Acta Otolaryngol. 2003 Aug;123(6):767-75
pubmed: 12953781
Oral Oncol. 1998 Sep;34(5):396-403
pubmed: 9861348
Oral Oncol. 2005 Jul;41(6):607-13
pubmed: 15975524
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
Br J Oral Maxillofac Surg. 1998 Aug;36(4):252-60
pubmed: 9762452
Patholog Res Int. 2015;2015:840739
pubmed: 26457223
J Oral Biol Craniofac Res. 2020 Oct-Dec;10(4):397-403
pubmed: 32775181
J Appl Oral Sci. 2020;28:e20190532
pubmed: 32348447
Mediators Inflamm. 2012;2012:516395
pubmed: 22496601
J Maxillofac Oral Surg. 2017 Mar;16(1):53-57
pubmed: 28286385
J Oral Maxillofac Pathol. 2019 Jan-Apr;23(1):19-27
pubmed: 31110412
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
Oral Dis. 2021 Nov;27(8):1977-1992
pubmed: 33290585
Oncology. 2005;68(4-6):314-25
pubmed: 16020958
Virchows Arch. 2002 Jun;440(6):594-7
pubmed: 12070598
Bioinformatics. 2001 Oct;17(10):977-87
pubmed: 11673243
BMJ. 2021 Mar 29;372:n160
pubmed: 33781993
Asia Pac J Clin Oncol. 2015 Sep;11(3):236-41
pubmed: 25560781
Nat Rev Cancer. 2020 Oct;20(10):555-572
pubmed: 32778778
Oral Oncol. 2017 Sep;72:38-47
pubmed: 28797460
Nucleic Acids Res. 2021 Jan 8;49(D1):D394-D403
pubmed: 33290554
Appl Immunohistochem Mol Morphol. 2014 Jan;22(1):65-71
pubmed: 23531848
J Cancer Res Ther. 2015 Jan-Mar;11(1):78-82
pubmed: 25879341